Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Map shows more than 1,900 measles cases across U.S. - 2Find Unexpected, yet invaluable treasure Excursion Rentals
- 3Windows to the Previous: An Excursion Through the World's Notable Engineering
- 4Abbott issues US device correction for some glucose monitors over faulty readings risk
- 5Vote in favor of your Number one method for commending a birthday
- Jubilant FoodWorks to scrap Dunkin’ franchise arrangement in India
- Turning into a Distributed Writer: My Composing Process
- 15 Preposterous Cosplay Ensembles That Will Blow You Away
- 'Backward and upward and tilted': Spaceflight causes astronauts' brains to shift inside their skulls
- How did this 20-light-year-wide 'Diamond Ring' form in space? Maybe a cosmic bubble burst
- Honda’s Biggest Flex Isn’t Its Superbikes, It’s Selling 500K Bikes In One Month
- Former elite Australian soldier charged with Afghan war crimes
- What's the new 'Knives Out' mystery about? Everything to know about 'Wake Up Dead Man,' including who's in the cast and what the reviews say.
- Going on a bad date is a drag. Worse? Ending up as a cautionary tale on TikTok.
